Status:
COMPLETED
Tumor Necrosis Factor-alpha Levels and Cardiac Functions in Type 1 Diabetes Mellitus
Lead Sponsor:
Sirnak State Hospital
Conditions:
Diabetes Mellitus, Type 1
Systolic Dysfunction
Eligibility:
All Genders
1-18 years
Brief Summary
The goal of this clinical trial is to learn about the effect of type 1 diabetes mellitus on cardiac functions and evaluate the correlation of the dysfunction with the tumor necrosis factor-α (TNF-α) a...
Detailed Description
Type 1 Diabetes Mellitus (T1DM) patients are at risk of developing cardiac dysfunction, a serious complication. Conventional echocardiography and tissue Doppler echocardiography are the most commonly ...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of Type 1 Diabetes Mellitus (T1DM) who have been under follow-up for at least 1 year (for the patient group)
Exclusion
- Having an additional cardiac anomaly
- Having an additional chronic medical condition
Key Trial Info
Start Date :
December 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06129448
Start Date
December 1 2023
End Date
February 1 2024
Last Update
April 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sirnak State Hospital
Şırnak, Turkey (Türkiye), 73000